Charleston Laboratories, Inc.

Charleston Laboratories, Inc. is engaged in developing innovative investigational treatments, focusing on pain management solutions, particularly for patients experiencing postoperative pain and associated opioid-induced side effects. Charleston Laboratories, Inc. was founded in 2007 and is headquartered in Jupiter, US.

The company specializes in creating novel treatments for acute pain, particularly through its flagship product, CL-108. The company secured USD 7. 42 million in Series B funding in September 2012, which marks its total amount raised to USD 7. 42 million and its current valuation at USD 52.

801 mn. The company has completed a total of 2 deals in its operational history. Charleston Laboratories, Inc. specializes in the development of novel investigational treatments, focusing primarily on CL-108, a product designed to address acute pain along with opioid-induced nausea and vomiting.

CL-108 is formulated to provide an effective solution to patients who are experiencing severe pain, particularly post-surgical patients, while also mitigating the adverse effects commonly associated with opioid medications. The company engages with healthcare providers and institutions in the U. S. market, offering its products directly to healthcare professionals and pharmacies.

Charleston Laboratories, Inc. operates on a revenue model involving direct sales and partnerships with healthcare providers and pharmacies. The company’s flagship product, CL-108, is marketed through a network of distributors to healthcare institutions, enabling physicians to prescribe it as part of pain management protocols. Revenue is generated through unit sales of CL-108 and potential subscription models for ongoing supply agreements with healthcare facilities, reflecting a comprehensive approach to market penetration and revenue generation.

Charleston Laboratories plans to utilize the funding raised in September 2012 to enhance its product development pipeline and expand its market reach. The company is focused on launching new products designed to improve pain management strategies for healthcare providers and patients. Furthermore, Charleston Laboratories aims to explore expansion opportunities beyond the U. S.

market, targeting international regions by 2015, to increase accessibility and adoption of CL-108 and future offerings.